| 1989 | Creation of ORPEA |
ORPEA Group is founded by current Chairman Dr Jean-Claude Marian. | |
| 1989-1995 |
Development focused on nursing homes |
The Group expands through the creation of 46 facilities, representing 4,600 nursing home beds. | |
| 1995 |
Consolidation and structuring of the organisation |
Following a period of brisk expansion, ORPEA reorganises itself in order to optimise its management costs. An administrative head office is created in the Paris region to organise and control the ORPEA Group's accounting, financial and employee-related matters. | |
| 1999 |
Development of a medium-term care offering |
ORPEA focuses on the creation and acquisition of postacute and rehabilitation care and psychiatric care clinics. | |
| 2002 |
IPO |
On 16 April 2002, ORPEA is successfully listed on the Second Marché of Euronext Paris. | |
| 2004 |
Expansion into Europe |
ORPEA opens its first two facilities in Italy. | |
| 2006 |
Further international expansion |
Acquisition of facilities in Switzerland (psychiatric clinic in Nyon, by Lake Geneva), Belgium (geriatric complex in the centre of Brussels) and Spain (Grupo Care, one of the market leaders in dependency care in Spain with 15 facilities representing 1,504 beds). | |
| 2007 |
Entering the DSS |
ORPEA is eligible for the Deferred Settlement Service (DSS), improving the stock's liquidity. | |
| 2008-2009 |
Structuring the European network |
ORPEA structures its presence in Europe by creating functional head offices in Belgium and Italy, and rolling out its quality policy at all of its facilities in Europe. | |
| 2010 | Major acquisition |
ORPEA carries out the largest acquisition in its history, with the strategic acquisition of Mediter - which notably owns a majority stake in the Mieux Vivre Group - and the acquisition of a 49% stake in Medibelge, representing a total of 4,866 beds at 57 facilities. | |
| 2011 | Strengthening of equity |
ORPEA successfully realizes a share capital increase in cash with shareholders’ preferential subscription rights of €203 million. |